Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles.
-
Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, Nakhla M, Bansal K, Ganatra S, Dani SS. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. Am J Cardiovasc Drugs. 2024 Nov; 24(6):791-799.
-
Kay J, Nikolov NP, Weisman MH. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis Rheumatol. 2024 Sep; 76(9):1323-1333.
-
Vishakha S, Navneesh N, Kurmi BD, Gupta GD, Verma SK, Jain A, Patel P. An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021). Anticancer Agents Med Chem. 2024; 24(8):590-626.
-
Vandenberg LN, Zoeller RT, Prins GS, Trasande L. Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA's criteria. Environ Health. 2023 04 21; 22(1):38.
-
Donovan SM, Abrams SA, Azad MB, Belfort MB, Bode L, Carlson SE, Dallas DC, Hettinga K, J?rvinen K, Kim JH, Lebrilla CB, McGuire MK, Sela DA, Neu J. Summary of the Joint National Institutes of Health and the Food and Drug Administration Workshop Titled "Exploring the Science Surrounding the Safe Use of Bioactive Ingredients in Infant Formula: Considerations for an Assessment Framework". J Pediatr. 2023 04; 255:30-41.e1.
-
Davidson BL, Gao G, Berry-Kravis E, Bradbury AM, B?nnemann C, Buxbaum JD, Corcoran GR, Gray SJ, Gray-Edwards H, Kleiman RJ, Shaywitz AJ, Wang D, Zoghbi HY, Flotte TR, Tauscher-Wisniewski S, Tifft CJ, Sahin M. Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. Mol Ther. 2022 07 06; 30(7):2416-2428.
-
Ebrahimian S, Kalra MK, Agarwal S, Bizzo BC, Elkholy M, Wald C, Allen B, Dreyer KJ. FDA-regulated AI Algorithms: Trends, Strengths, and Gaps of Validation Studies. Acad Radiol. 2022 04; 29(4):559-566.
-
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
-
Berg CJ, Barker DC, Sussman S, Getachew B, Pulvers K, Wagener TL, Hayes RB, Henriksen L. Vape Shop Owners/Managers' Opinions About FDA Regulation of E-Cigarettes. Nicotine Tob Res. 2021 02 16; 23(3):535-542.
-
Berg CJ, Barker DC, Meyers C, Weber A, Park AJ, Patterson A, Dorvil S, Fairman RT, Huang J, Sussman S, Livingston MD, Wagener TL, Hayes RB, Pulvers K, Getachew B, Schleicher N, Henriksen L. Exploring the Point-of-Sale Among Vape Shops Across the United States: Audits Integrating a Mystery Shopper Approach. Nicotine Tob Res. 2021 02 16; 23(3):495-504.